Cancer cells expand through mutations – but not just through mutations. They also change their behavior in the absence of underlying genetic alterations. Such plasticity helps the cells both adapt to the cellular stress fueled by out-of-control growth and resist targeted and chemotherapies alike. Investigators from Memorial Sloan Kettering Cancer Center and Huazhong Agricultural University have gained new insights into the underlying mechanisms of plasticity.
Cancer cells expand through mutations – but not just through mutations. They also change their behavior in the absence of underlying genetic alterations. Such plasticity helps the cells both adapt to the cellular stress fueled by out-of-control growth and resist targeted and chemotherapies alike. Investigators from Memorial Sloan Kettering Cancer Center and Huazhong Agricultural University have gained new insights into the underlying mechanisms of plasticity.
Researchers from Lanzhou University and Southern Medical University (China) have presented the discovery of a structurally distinct pyrimidine-based chemotype for the inhibition of KRAS G12C.
Bio-Thera Solutions Ltd. has synthesized new antibody-drug conjugates comprising trastuzumab targeting HER2 (erbB2) covalently linked to exatecan through a linker reported to be useful for the treatment of cancer, inflammation, autoimmune disorders and infections.
Erasca Inc. priced an upsized public offering to raise $225 million to fund development of its therapies for patients with RAS/MAPK pathway-driven cancers.
Avacta Therapeutics (Avacta Group plc) has obtained IND clearance from the FDA for FAP-Exd (AVA-6103), a Precision peptide-drug conjugate based on exatecan.
Cancer cells expand through mutations – but not just through mutations. They also change their behavior in the absence of underlying genetic alterations. Such plasticity helps the cells both adapt to the cellular stress fueled by out-of-control growth and resist targeted and chemotherapies alike. Investigators from Memorial Sloan Kettering Cancer Center and Huazhong Agricultural University have gained new insights into the underlying mechanisms of plasticity.
Antibody-drug conjugates (ADCs) are promising biotherapeutics composed of an antibody plus a cytotoxic payload via a chemical linker, thus allowing the delivery of cytotoxic payload to target cancer cells. Among cancer glycoproteins studied in cancer research, mucin-1 (MUC1) is among the most extensively researched.
Crinetics Pharmaceuticals Inc. has described drug conjugates consisting of a non-peptide moiety targeting G protein-coupled receptors (GPCRs) covalently linked to a chemotherapeutic moiety through a linker reported to be useful for the diagnosis and treatment of cancer.
Hangzhou Polymed Biopharmaceuticals Inc. has disclosed proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently bonded to an EGFR del19/Thr790Met/Cys797Ser triple mutant and/or EGFR Leu858Arg/Thr790Met/Cys797Ser triple mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.
